Drug data last refreshed 33m ago · AI intelligence enriched 2w ago
ALDARA is a topical cream formulation approved in 1997 for dermatological indications. The product is a small molecule immune response modifier administered through topical application. It represents a established therapy in the dermatology space with a mature commercial profile.
As LOE approaches, the commercial team faces moderate competitive pressure (30/100) with limited growth opportunities, signaling potential headcount optimization and strategic repositioning efforts.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
H5N1 With or Without Topical Aldara in Healthy Adults
Aldara for the Treatment of Large and/or Multiple sBCC
Working on ALDARA offers limited career advancement given the approaching loss of exclusivity and minimal clinical pipeline activity. Roles are concentrated in R&D with only 2 linked open positions, suggesting a consolidating team structure.
Worked on ALDARA at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
2 open roles linked to this drug